Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 3/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.40 |
| ▸ | BACE1 | P56817 | 3/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.36 |
| ▸ | MME | P08473 | 3/20 | 0.34 |
| ▸ | ANPEP | P15144 | 2/20 | 0.34 |
| ▸ | ECE1 | P42892 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30799951 | 0.98 | PTPN1 (0.42) | LTA4HPTPN1BACE1OPRD1 | |
| SCHEMBL30607941 | 0.94 | BACE1 (0.41) | LTA4HPTPN1BACE1 | |
| SCHEMBL29511114 | 0.94 | BACE1 (0.41) | LTA4HPTPN1BACE1 | |
| SCHEMBL29630414 | 0.92 | OPRD1 (0.36) | LTA4HOPRD1MMEANPEP | |
| SCHEMBL29590996 | 0.92 | OPRD1 (0.36) | LTA4HOPRD1MMEANPEP | |
| SCHEMBL29630382 | 0.90 | BACE1 (0.36) | LTA4HBACE1MMEANPEPECE1 | |
| SCHEMBL30799934 | 0.90 | BACE1 (0.45) | PTPN1BACE1OPRD1 | |
| SCHEMBL34470404 | 0.90 | MME (0.36) | LTA4HOPRD1MMEANPEP | |
| SCHEMBL29461611 | 0.90 | BACE1 (0.39) | LTA4HPTPN1BACE1MMEECE1 | |
| SCHEMBL29749372 | 0.89 | MME (0.36) | LTA4HMMEANPEPECE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024132726-A1 | SERUM PEPTIDE PATTERNS FOR DIAGNOSTICS OF ACUTE ISCHEMIC STROKE IN HUMANS AND DIFFERENTIAL DIAGNOSIS OF ACUTE ISCHEMIC STROKE FROM INTRACRANIAL HEMORRHAGIC STROKE | UNIWERSYTET GDANSKI (PL) | 2024-06-27 | — | — | WO | disclosed |
| US-20240116985-A1 | STAPLED PEPTIDES AND METHODS THEREOF | PARABILIS MEDICINES, INC. | 2024-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240116985-A1 | STAPLED PEPTIDES AND METHODS THEREOF | CTNNB1, APC, CTNNA1 | LTA4H 4132/4885PTPN1 2414/4885BACE1 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.